Download PDF
Exp Clin Endocrinol Diabetes 2013; 121(05): 272-279
DOI: 10.1055/s-0033-1334955
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Multiple Statistical Methods for Assessing Differential Gene Expression in Microarray Data of Diabetic Model Rats to Predict the Molecular Mechanism of Atorvastatin on Anti-Atherogenesis

L. Xu
1   Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
,
B. Feng
1   Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
,
H. Wang
1   Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
,
X. Li
1   Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
› Author Affiliations
Further Information

Publication History

received 30 January 2013
first decision 30 January 2013

accepted 12 February 2013

Publication Date:
28 February 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

Many evidences indicate that statins have pleiotropic effects that are lipid-lowering independent. These effects could suggest attenuation of many of the stages critical to atherosclerosis. However, the specific molecular mechanisms of statins on atherogenesis are still unknown. The goal is to detect and analyze the altered gene expression of the artery after atorvastatin treatment in streptozocin (STZ)-induced diabetic rats, and to predict the possible cholesterol-independent effects of atorvastatin on anti-atherogenesis.

Methods:

A total of 33 Sprague Dawley (SD) rats were randomly divided into 3 groups: control group, diabetic group, and diabetic group with atorvastatin treatment (receiving 50 mg/kg qd atorvastatin). Rats were sacrificed at the end of 4 weeks, and the aortas were obtained. The pathological changes were observed by Hematoxylin and eosin (HE) staining. A cDNA microarray analysis was carried out, and the results were analyzed by the random variance model (RVM) t-test, Stc analysis, Stc-Gene Ontology (GO) analysis, Stc-pathway analysis, and GeneFunNet analysis. Then reverse transcription polymerase chain reaction (RT-PCR) was used to evaluate the mRNA expression of Cathepsin S (Cat S),Which was one of the significant genes obtained by statistical analysis, in the aortas of rats in control group (Wistar rats), DM group (Goto Kakisaki rats) and atorvastatin treated DM group (Goto Kakisaki rats with 50 mg/kg qd atorvastatin) for 12 weeks.

Results:

A total of 1 073 differential expression genes were found in the 3 groups. 2 tendency profiles of gene expression, which represented the medicine effect, were picked out by Stc analysis of gene expression. The main functions of genes and the significant pathways in the 2 profiles were figured out by Stc-go analysis and Stc-pathway analysis. The core regulatory factors in the co-expression network were shown by GeneFunNet analysis. Among these significant genes, Cat S was chosen to be further evaluated as a target gene. Expression of Cat S was upregulated in the aortas of the diabetic rats and downregulated with statistical significance by atorvastatin treatment.

Conclusions:

Atorvastatin can influence the expression of many genes and signal pathways, some may be significant and produce their marked effects on all of the processes of atherogenesis. Cat S is one of them. These data thus predict the possible molecular mechanism of pleiotropic effects of atorvastatin, which is useful for further experimental design.

Key words

diabetes - atorvastatin - atherosclerosis - statistical methods - microarray - cathepsin S
 

  • References

  • 1 Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146
    CrossrefPubMedGoogle Scholar
  • 2 Colhoun HM, Betteridge DJ, Durrington PN et al. CARDS investigators . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
    CrossrefPubMedGoogle Scholar
  • 3 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
    CrossrefPubMedGoogle Scholar
  • 4 Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125
    CrossrefPubMedGoogle Scholar
  • 5 Fonarow GC, Wright RS, Spencer FA et al. National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 h of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96: 611-616
    CrossrefPubMedGoogle Scholar
  • 6 Zhou Q, Liao JK. Pleiotropic effects of statins. – Basic research and clinical perspectives. Circ J 2010; 74: 818-826
    CrossrefPubMedGoogle Scholar
  • 7 Feng B, Xu L, Wang H et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta 2011; 1812: 1130-1137
    CrossrefPubMedGoogle Scholar
  • 8 Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19: 2448-2455
    CrossrefPubMedGoogle Scholar
  • 9 Yang H, Crawford N, Lukes L et al. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005; 22: 593-603
    CrossrefPubMedGoogle Scholar
  • 10 Clarke R, Ressom HW, Wang A et al. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 2008; 8: 37-49
    CrossrefPubMedGoogle Scholar
  • 11 Ramoni MF, Sebastiani P, Kohane IS. Cluster analysis of gene expression dynamics. Proc Natl Acad Sci USA 2002; 99: 9121-9126
    CrossrefPubMedGoogle Scholar
  • 12 Miller LD, Long PM, Wong L et al. Optimal gene expression analysis by microarrays. Cancer Cell 2002; 2: 353-361
    CrossrefPubMedGoogle Scholar
  • 13 Ashburner M, Ball CA, Blake JA et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29
    CrossrefPubMedGoogle Scholar
  • 14 Dupuy D, Bertin N, Hidalgo CA et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat Biotechnol 2007; 25: 663-668
    CrossrefPubMedGoogle Scholar
  • 15 Schlitt T, Palin K, Rung J et al. From gene networks to gene function. Genome Res 2003; 13: 2568-2576
    CrossrefPubMedGoogle Scholar
  • 16 Kanehisa M, Goto S, Kawashima S et al. The KEGG resource for deciphering the genome. Nucleic Acids Res 2004; 32: D277-D280
    CrossrefPubMedGoogle Scholar
  • 17 Yi M, Horton JD, Cohen JC et al. WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics 2006; 19: 7-30
    PubMedGoogle Scholar
  • 18 Draghici S, Khatri P, Tarca AL et al. A systems biology approach for pathway level analysis. Genome Res 2007; 17: 1537-1545
    CrossrefPubMedGoogle Scholar
  • 19 Pujana MA, Han JD, Starita LM et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007; 39: 1338-1349
    CrossrefPubMedGoogle Scholar
  • 20 Prieto C, Risueno A, Fontanillo C et al. Human gene coexpression landscape: confident network derived from tissue transcriptomic profiles. PLoS One 2008; 3: e3911
    CrossrefPubMedGoogle Scholar
  • 21 Carlson MR, Zhang B, Fang Z et al. Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics 2006; 3: 7-40
    PubMedGoogle Scholar
  • 22 Barabasi AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet 2004; 5: 101-113
    CrossrefPubMedGoogle Scholar
  • 23 Ravasz E, Somera AL, Mongru DA et al. Hierarchical organization of modularity in metabolic networks. Science 2002; 297: 1551-1555
    CrossrefPubMedGoogle Scholar
  • 24 Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719
    CrossrefPubMedGoogle Scholar
  • 25 Bracht L, Caparroz-Assef SM, Magon TF et al. Topical anti-inflammatory effect of hypocholesterolaemic drugs. J Pharm Pharmacol 2011; 63: 971-975
    CrossrefPubMedGoogle Scholar
  • 26 Rikitake Y, Kawashima S, Takeshita S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96
    CrossrefPubMedGoogle Scholar
  • 27 Wågsäter D, Zhu C, Björkegren J et al. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med 2011; 28: 247-253
    PubMedGoogle Scholar
  • 28 Sukhova GK, Zhang Y, Pan JH et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003; 111: 897-906
    CrossrefPubMedGoogle Scholar
  • 29 Schrijvers DM, De Meyer GR, Herman AG et al. Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 2007; 73: 470-480
    CrossrefPubMedGoogle Scholar
  • 30 Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 2004; 61: 671-682
    CrossrefPubMedGoogle Scholar
  • 31 Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22
    CrossrefPubMedGoogle Scholar
  • 32 Duval C, Chinetti G, Trottein F et al. The role of PPARs in atherosclerosis. Trends Mol Med 2002; 8: 422-430
    CrossrefPubMedGoogle Scholar
  • 33 Evans JL, Goldfine ID, Maddux BA et al. Oxidative stress and stressactivated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002; 23: 599-622
    CrossrefPubMedGoogle Scholar
  • 34 Li JP, Fu YN, Chen YR et al. JNK pathway-associated phosphatase dephosphorylates focal adhesion kinase and suppresses cell migration. J Biol Chem 2010; 285: 5472-5478
    CrossrefPubMedGoogle Scholar
  • 35 Yano M, Matsumura T, Senokuchi T et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007; 100: 1442-1451
    CrossrefPubMedGoogle Scholar
  • 36 Sugamura K, Sugiyama S, Matsuzawa Y et al. Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. Circ J 2008; 72: 1193-1197
    CrossrefPubMedGoogle Scholar
  • 37 Laufs U, Kilter H, Konkol C et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-920
    CrossrefPubMedGoogle Scholar
  • 38 Cicha I, Schneiderhan-Marra N, Yilmaz A et al. Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo. Arterioscler Thromb Vasc Biol 2004; 24: 2046-2050
    CrossrefPubMedGoogle Scholar
  • 39 Takemoto M, Sun J, Hiroki J et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62
    CrossrefPubMedGoogle Scholar
  • 40 Maack C, Kartes T, Kilter H et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003; 108: 1567-1574
    CrossrefPubMedGoogle Scholar
  • 41 Dichtl W, Dulak J, Frick M et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63
    CrossrefPubMedGoogle Scholar
  • 42 Hölschermann H, Schuster D, Parviz B et al. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 2006; 185: 240-245
    CrossrefPubMedGoogle Scholar
  • 43 Laufs U, La Fata V, Plutzky J et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135
    CrossrefPubMedGoogle Scholar
  • 44 Djaldetti M, Salman H, Bergman M et al. Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Exp Mol Pathol 2006; 80: 160-164
    CrossrefPubMedGoogle Scholar
  • 45 Tang TY, Howarth SP, Miller SR et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009; 53: 2039-2050
    CrossrefPubMedGoogle Scholar
  • 46 Schupp N, Schmid U, Heidland A et al. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008; 199: 278-287
    CrossrefPubMedGoogle Scholar
  • 47 Liu W, Spero DM. Cysteine protease cathepsin S as a key step in antigen presentation. Drug News Perspect 2004; 17: 357-363
    CrossrefPubMedGoogle Scholar
  • 48 Liu J, Sukhova GK, Sun SJ et al. Lysosomal cysteine proteases in atherosclerosis, Arterioscler. Thromb Vasc Biol 2004; 24: 1359-1366
    CrossrefPubMedGoogle Scholar
  • 49 Sukhova GK, Shi GP, Simon DI et al. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-583
    CrossrefPubMedGoogle Scholar
  • 50 Tanimoto A, Murata Y, Wang KY et al. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem 2008; 283: 4643-4651
    CrossrefPubMedGoogle Scholar
  • 51 Shiraya S, Miyake T, Aoki M et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009; 202: 34-40
    CrossrefPubMedGoogle Scholar